ERBB2 and triple-negative breast carcinoma: The RCB categories have been shown to correlate with long-term survival outcomes across triple-negative breast cancer (TNBC) and HER2 breast cancer subtypes and several clinical study groups, such as I-SPY [1, 2], ACOSOG (Z11103), CALGB (40601, 40603), NSABP (B-40, B-41) and ABCSG [22].